Latest News - Epilepsy & Seizure Disorders

Tuesday, September 04, 2018

Phase 3 Trial of Low-Dose Fenfluramine for Lennox-Gastaut Syndrome Is Enrolling Patients

In a phase 2 open-label study of the orphan drug fenfluramine (ZX008; Zogenix, Emeryville, CA) for treatment of patients with Lennox-Gastaut Syndrome (LGS) refractory to treatment, the majority of pat…

Read the full story

Friday, August 24, 2018

Stiripentol Approved by FDA for Treatment of Dravet Syndrome

The Food and Drug Administration (FDA) has approved stiripentol (Diacomit; Biocodex, Gentilly, France) as an adjunct to clobazam for the treatment of seizures associated with Dravet syndrome (DS). Sti…

Read the full story

Monday, August 13, 2018

New Drug Application Accepted for Midazolam Nasal Spray for Treating Patients with Acute Repetitive Seizures

The Food and Drug Administration (FDA) has accepted a new drug application (NDA) filing for midazolam nasal spray (USL261; UCB, Atlanta, GA) for the treatment of persons with epilepsy who experience a…

Read the full story

Saturday, August 04, 2018

Folic Acid During Pregnancy for Women Taking Antiepileptic Drugs May Improve Language Development for Their Children

A study published in Neurology evaluated the relationship between language delays in children born to women taking antiepileptic drugs (AEDs) with and without folic acid supplementation. The study was…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Thursday, July 12, 2018

Significant Seizure Reduction in Persons With Dravet Syndrome With ZX008 in Phase 3 Trial

Adjunctive treatment of persons with Dravet syndrom with the investigational compound, low-dose fenfluramine hydrochloride (ZX008; Zogenix, Emeryville, CA), has been shown to have a statistically sign…

Read the full story

Tuesday, June 26, 2018

Epidiolex Approved for Treatment of Dravet and Lennox-Gastaut Syndromes

Yesterday, the Food and Drug Administration (FDA) approved cannabidiol (CBD) oral solution (Epidiolex; GW Research, Carlsbad, CA) for the treatment of seizures associated with Lennox-Gastaut syndrome …

Read the full story

Wednesday, June 13, 2018

Medtronic Deep Brain Stimulation Clinician Programmer Receives FDA Approval

Medtronic announced that the Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. The Activa Programming A…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Wednesday, May 23, 2018

New Type of Vertigo Defined That May Be Treatable

Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from serious causes of vertigo (eg, …

Read the full story

Thursday, May 17, 2018

Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed that adding oral CBD to …

Read the full story

Wednesday, May 16, 2018

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures.  The company expects t…

Read the full story

Tuesday, May 01, 2018

Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures

The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce frequency of partial-ons…

Read the full story

Friday, April 27, 2018

Perampanel Safety, Efficacy, and Predictors of Major Response

Perampanel (FYCOMPA; Eisai, Woodcliff Lake, NJ) is approved for use as monotherapy for treatment of partial-onset seizures (POS) with or without secondarily generalized seizures (SGS) and as adjunctiv…

Read the full story

Thursday, April 19, 2018

Advisory Committee Supports Approval of Oral Cannabidiol for Dravet Syndrome and Lennox-Gastaut Syndrome

The Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) unanimously recommended supporting the approval of the investigational cannabidiol oral sol…

Read the full story
Load More